DOI · e01.org

Novel RET Inhibitor BLU-667 Offers Promise for RET+ Advanced NSCLC

— · Default Digital Object Group · 2019

  • DOI 10.1200/adn.19.190332
  • Publisher OpenAlex
  • Type dataset
  • Issued 2019

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Default Digital Object Group · OpenAlex · dataset · 2019

Abstract

The novel selective RET inhibitor BLU-667 demonstrated promising antitumor activity and was well tolerated in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC), according to a study presented on June 3 (Abstract 9008).

Open the resolved locator · 10.1200/adn.19.190332

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:01 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.1200/adn.19.190332
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.